BackNeoleukin Therapeutics Overview

Neoleukin Therapeutics Current Cash

Neoleukin Therapeutics's current cash is $120M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$124.16M
75.44% YoYΔ $53.39M vs prior year quarter

Peer average

Loading

Neoleukin Therapeutics Current Cash History

Loading

Neoleukin Therapeutics vs. peers: Current Cash Comparison

Loading

Neoleukin Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Neoleukin Therapeutics (NLTX) FAQ

As of the most recent data (March 2026), NLTX shows a current cash of $120M. That compares with $71M in the prior-year period — up 75.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NLTX's current cash is now $120M (was $71M) — a 75.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Neoleukin Therapeutics is outperforming or lagging.

Tracking NLTX's current cash over time shows whether Neoleukin Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $120M That compares with $71M in the prior-year period — up 75.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Neoleukin Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $120M) with ownership activity and broader fundamentals.

Neoleukin Therapeutics's current cash is $120M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.